Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Interim PFO and COO | September 23, 2024 | September 25, 2024 |
| Fortress Biotech, Inc.FBIO · Entity 6822 | Chief Financial Officer | October 01, 2026 | October 02, 2026 |
| MUSTANG BIO, INC.MBIO · Entity 8350 | Director | December 30, 2025 | December 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVENUE THERAPEUTICS, INC.
Report date September 23, 2024 · Filed September 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 65,000 |
Reported balance
After 2024-09-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-09-23 · Grant · Acquired 65,000 · Balance 65,000 F1: Represents an award of 65,000 restricted stock units which will vest in equal installments at September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Change in Control event (as defined in the Avenue Therapeutics, Inc. 2015 Incentive Plan); the amount will be distributed in the form of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of 65,000 restricted stock units which will vest in equal installments at September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Change in Control event (as defined in the Avenue Therapeutics, Inc. 2015 Incentive Plan); the amount will be distributed in the form of the Issuer's common stock.
Fortress Biotech, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 1,652,761 |
Reported balance
After 2026-10-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 1,190 · Balance 1,652,761 F1: The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2: Total holdings include 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: Total holdings include 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units.
MUSTANG BIO, INC.
Report date December 30, 2025 · Filed December 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 286 |
Reported balance
After 2025-12-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-30 · Purchase · Acquired 247 · Balance 286 F1: Represents a private purchase of 247 shares of common stock from another member of the board of directors of the Issuer. F2: Effective January 15, 2025, the Issuer effected a one-for-fifty reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a private purchase of 247 shares of common stock from another member of the board of directors of the Issuer.
F2: Effective January 15, 2025, the Issuer effected a one-for-fifty reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 00:30 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 1,190 | $1.82 | $2,164.61 |
DisclosureSEC source: 0001930732-26-000006 · form4-10012026_041005.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,652,761 F1 · shares: The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · balance_after: Total holdings include 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 01:50 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001930732-26-000003 · form4-06252026_010600.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,651,571 F1 · shares: Represents an award of 400,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in four equal annual installments, with the first installment vesting on January 5, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Vested restricted stock units will be settled in shares of the Issuer's common stock. F2 · balance_after: Total holdings include 1,230,000 shares underlying previously granted deferred restricted stock units. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 20:05 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 2,967 | $2.18 | $6,456.19 |
DisclosureSEC source: 0001930732-26-000002 · form4-04012026_040401.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,251,571 F1 · shares: The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · balance_after: Total holdings include 1,230,000 shares underlying deferred restricted stock units. Read SEC document |
| December 30, 2025 Filed Dec 30, 2025 21:15 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK, PAR VALUE $0.0001 | 247 | $0.96 | $237.61 |
DisclosureSEC source: 0001104659-25-125227 · tm2534509-1_4seq1.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286 F1 · shares: Represents a private purchase of 247 shares of common stock from another member of the board of directors of the Issuer. F2 · balance_after: Effective January 15, 2025, the Issuer effected a one-for-fifty reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 20:30 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 2,711 | $1.31 | $3,548.70 |
DisclosureSEC source: 0001930732-25-000004 · form4-10022025_041001.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,248,604 F1 · shares: The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · balance_after: Total holdings include 1,230,000 shares underlying deferred restricted stock units. Read SEC document |
| April 01, 2025 Filed Apr 1, 2025 20:20 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 5,000 | $1.22 | $6,077.50 |
DisclosureSEC source: 0001415889-25-009369 · form4-04012025_080413.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,245,893 F1 · shares: The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · balance_after: Total holdings include 1,230,000 shares underlying deferred restricted stock units. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 21:30 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030071 · form4-12232024_041201.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,240,893 F1 · shares: Represents an award of 1,000,000 restricted stock units which will vest in 16 equal quarterly installments beginning after December 20, 2024. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Corporate Transaction (as defined in the Fortress Biotech, Inc. 2013 Stock Incentive Plan); the amount will be distributed in the form of the Issuer's common stock. F2 · balance_after: Total holdings include 1,230,000 shares underlying deferred restricted stock units. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 20:15 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 2,625 | $1.23 | $3,224.29 |
DisclosureSEC source: 0001415889-24-024183 · form4-10012024_041004.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,893 F1 · shares: The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · balance_after: Total holdings include 230,000 shares underlying deferred restricted stock units. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 20:53 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-102834 · tm2424771-2_4seq1.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Interim PFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 F1 · shares: Represents an award of 65,000 restricted stock units which will vest in equal installments at September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Change in Control event (as defined in the Avenue Therapeutics, Inc. 2015 Incentive Plan); the amount will be distributed in the form of the Issuer's common stock. F1 · balance_after: Represents an award of 65,000 restricted stock units which will vest in equal installments at September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Change in Control event (as defined in the Avenue Therapeutics, Inc. 2015 Incentive Plan); the amount will be distributed in the form of the Issuer's common stock. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 12:42 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 500 | $7.50 | $3,750.00 |
DisclosureSEC source: 0001104659-24-079409 · tm2419335-1_4seq1.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500 Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:06 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 2,352 | $1.70 | $3,998.40 |
DisclosureSEC source: 0001104659-24-042504 · tm2410608-1_4seq1.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,268 F1 · shares: The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · balance_after: Total holdings include 230,000 shares underlying deferred restricted stock units. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 21:05 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 140,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-128788 · tm2333573-1_4seq1.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,916 F1 · shares: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. F2 · shares: Represents an award of 140,000 restricted stock units which will vest in 16 equal quarterly installments after the grant date, December 20, 2023. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Corporate Transaction (as defined in the Fortress Biotech, Inc. 2013 Stock Incentive Plan); the amount will be distributed in the form of the Issuer's common stock. F3 · balance_after: Total holdings include 230,000 shares underlying deferred restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:09 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantEmployee stock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001104659-23-078098 · tm2320488d5_4seq1.xml · derivative · entry 1 Jin David · CIK 0001930732 · Interim PFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-06-30 F1 · derivative.exercise_date: The option vests in accordance with the following schedule: (i) 25% of the shares subject to the option vest on August 1, 2023; (ii) 25% of the shares subject to the option vest on August 1, 2024; (iii) 25% of the shares subject to the option vest on August 1, 2025; and (iv) 25% of the shares subject to the option vest on August 1, 2026. F2 · derivative.underlying_shares: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:06 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 35,928 | $0.84 | $29,999.88 |
DisclosureSEC source: 0001104659-23-021541 · tm236803-1_4seq1.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,438,757 F1 · balance_after: The total holdings include 1,350,000 shares underlying deferred restricted stock units. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 21:14 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 5,000 | $0.56 | $2,800.00 |
DisclosureSEC source: 0001104659-22-124100 · tm2231877-1_4seq1.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,402,829 F1 · shares: Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. Under the ESPP, 5,000 shares is the maximum amount an individual employee may purchase during an offering period. F2 · balance_after: The total holdings include 1,350,000 shares underlying restricted stock units. Read SEC document |
| October 26, 2022 Filed Oct 28, 2022 21:02 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 1,350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-112522 · tm2229153-2_4seq1.xml · nonDerivative · entry 1 Jin David · CIK 0001930732 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,397,829 F1 · shares: Represents an award of 1,350,000 restricted stock units which will vest in 48 equal monthly installments after the grant date, October 26, 2022. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Corporate Transaction (as defined in the Fortress Biotech, Inc. 2013 Stock Incentive Plan); the amount will be distributed in the form of the Issuer's common stock. F2 · balance_after: The total holdings include 1,350,000 shares underlying restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.